drugset
drugset / Trial / NCT00765999

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00765999 ↗

Phase 3 Completed 1559 enrolled Forest Laboratories Ironwood Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).

Timeline

Start
2008-10-31
Primary completion
2012-01-31
Completion
2012-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide 145 ug Oral
Subject Linaclotide Peptide 290 ug Oral

Indications

constipation disorder irritable bowel syndrome